Table 2.
Comparative Overview of EBV-Associated Lymphomas in Humans and Simian EBV-Like Virus-Associated Diseases in Rabbits
| Lymphoma type | Phenotype | Typical latent period | EBV positivity | EBV gene expression | Latency type |
|---|---|---|---|---|---|
| Burkitt’s ML | B cell | 3–8 years | 100% (endemic), 15–85% (sporadic) | EBNA1+ | I |
| Opportunistic ML | B cell | <1 year post-transplant, 5–10 years post-HIV70–80% | 100% | EBNA1+, EBNA2+, LMP1+ | III |
| Fatal IM | B cell | <6 months | 100% | EBNA1+, EBNA2+, LMP1+ | III |
| PAL | B cell | 33 years post-treatment | 100% | EBNA2+, LMP1+ | III |
| VAHS/fatal IM (T-cell ML) | T cell | <6 months | 100% | ? | |
| T-cell ML (AILD/pleomorphic) | T cell | >30 years | 40%? | EBNA2−, LMP1+ | II |
| Nasal T/NK cell ML | T/NK cell | >30 years | 100% | EBNA1+, LMP1+/− | II |
| Hodgkin’s disease | >10 years | 39–90% | EBNA1+, LMP1+ | II | |
| Rabbit ML model by cynomolgus EBV | T cell | 2–5 months | 100% | EBNA1+, EBNA2−, LMP1−? | I |
| Rabbit fatal LPD with VAHS model by baboon EBV (HVP) | T cell | 3 weeks–3 months | 100% | HVP-EBNA1 transcript+, HVP-EBNA2 transcript+, HVP-LMP1 transcript+ | III |
This table was modified from the table in the textbook. 41
ML, malignant lymphoma; PAL, pyothorax-associated lymphoma; VAHS, virus-associated hemophagocytic syndrome; IM, infectious mononucleosis; AILD, angioimmunoblastic lymphadenopathy-like; LPD, lymphoproliferative disorders; HVP, Herpesvirus papio.